Immune alterations in untreated and treated multiple myeloma
1Department of Hematology-Oncology, St. Francis Hospital and Medical Center, Hartford, CT, USA. c_dasanu@yahoo.com
Summary
Multiple myeloma patients face a higher risk of developing second cancers due to immune system defects. Further research is needed on novel therapies and their impact on cancer incidence.
Area of Science:
- Immunology
- Oncology
- Hematology
Background:
- Multiple myeloma is associated with an increased incidence of secondary malignancies.
- Immune dysfunction in multiple myeloma may contribute to the development of additional cancers.
Observation:
- Myeloma patients exhibit impairments in both cellular and humoral immunity.
- These immune defects increase susceptibility to infections and secondary cancers.
- Therapeutic advances have made multiple myeloma a chronic disease, potentially leading to cumulative immunosuppression.
Findings:
- The review explores the link between immune impairments in multiple myeloma and increased cancer risk.
- Novel anti-myeloma therapies, including lenalidomide, may influence the rate of second cancers.
- The precise impact of current treatments on secondary malignancy incidence requires further investigation.
Implications:
- Understanding immune defects is crucial for managing myeloma patients.
- Further research is needed to clarify the long-term effects of novel therapies on secondary cancer risk.
- This knowledge can inform strategies to mitigate risks and improve patient outcomes.
